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 Th e role of dopamine and its receptors in 
determination of blood pressure has been 
well established; dopamine regulates vas-
cular smooth muscle contractility and 
renal sodium transport. 1 Dopamine is a 
neurotransmitter involved in a variety of 
brain functions, and dopaminergic recep-
tors have been studied extensively in the 
context of various central nervous system 
disorders, ranging from psychiatric dis-
eases (schizophrenia, drug addiction, 
autism, attention-defi cit and hyperactivity 
disorders) to movement and neuroendo-
crine disorders (Parkinson ’ s disease, 
hyperprolactinemia). Dopamine receptors 
are coupled to G proteins and include fi ve 
subtypes, more broadly classifi ed into D 1 -
like receptors (D 1 and D 5 ) that stimulate 
adenylyl cyclase activity and D 2 -like 
receptors (D 2 , D 3 , and D 4 ) that inhibit 
adenylyl cyclase. Each subtype has been 
implicated in the regulation of renal 
sodium transport and blood pressure con-
trol, and members of both classes are 
expressed in the kidney. 2 Th e strongest 
and most direct evidence for blood pres-
sure eff ect exists for the D 1 receptor. In 
humans, D 1 receptors localize to intrare-
nal vasculature, proximal and distal con-
voluted tubules, and collecting ducts. 3 In 
the proximal tubule, D 1 receptors mediate 
the natriuretic eff ect of dopamine by cyclic 
adenosine monophosphate – mediated 
inhibition of sodium transport. 4,5 Th is 
eff ect is counteracted by angiotensin II, 
which exerts an opposing eff ect via angio-
tensin II type 1 receptors. Accordingly, 
animal models with defective D 1 receptors 
have increased blood pressure. 5,6 In 
humans, fenoldopam (a selective 
dopamine D 1 receptor agonist) decreases 
blood pressure, whereas ecopipam 
(a selective dopamine D 1 receptor 
 antagonist) has the opposite eff ect. 7,8 
 The dopamine D 1 receptor ( DRD1 ) 
gene is intronless, resides on chromosome 
5q35.1, and encodes a 446-amino acid 
protein. 9 Alternative transcription initia-
tion sites result in two transcript variants 
of this gene, but the coding sequence 
remains unaltered and is highly conserved 
across species. Polymorphisms in  DRD1 
have been initially studied in association 
with various neuropsychiatric diseases. 
Th ese studies characterized two noncod-
ing polymorphic sites in the 5  -untrans-
lated region (5  -UTR) ( – 48A>G and 
 – 94G>A). Considering the compelling 
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 Polymorphisms in the genes involved in the dopaminergic system have 
been implicated in susceptibility to hypertension. A new study by Fung 
 et al. takes a closer look at the association of genetic variants in the 
dopamine D 1 receptor gene ( DRD1 ) with blood pressure and renal 
parameters. Although the study does not confirm an association with 
blood pressure, it suggests a new link between a common variant in 
the 5  -untranslated region of the  DRD1 gene and low glomerular 
filtration rate. 
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evidence for the D 1 receptor ’ s role in renal 
physiology, several groups assessed these 
two polymorphisms in relationship to the 
risk of hypertension and renal traits in 
humans. Unfortunately, most of these 
analyses suff er from limitations inherent 
to early candidate gene studies, such as 
small sample size, inadequate correction 
for multiple testing, phenotypic hetero-
geneity, selection bias, and insuffi  cient 
assessment of population stratifi cation. 
Not surprisingly, the results have been 
inconclusive and somewhat confl icting 
( Table 1 ). 
 Fung and colleagues 10 (this issue) re-
examine the potential role of genetic 
variation in DRD1 in determination of 
blood pressure and renal function. Th e 
authors start by resequencing the  DRD1 
gene in 27 unrelated white individuals in 
order to discover new polymorphic sites. 
Th e two previously described  variants, 
 – 48A>G and  – 94G>A, were confi rmed 
to occur at a relatively high frequency of 
15 % and 30 % , respectively, and no other 
single-nucleotide polymorphisms (SNPs) 
were identifi ed by this eff ort. Both of the 
5  -UTR polymorphisms were tested for 
associations with systolic and diastolic 
blood pressure and with several renal 
parameters (serum creatinine, estimated 
glomerular fi ltration rate (eGFR), urine 
and serum urate, and fractional excretion 
of uric acid). Initial association testing 
was performed in a family-based cohort, 
aft er appropriate adjustments for family 
structure in the analyses. Consistent with 
prior studies, all tested traits had high 
heritability in the family cohort (41 % –
 78 % ). No signifi cant associations were 
detected for systolic or diastolic blood 
pressure, but one of the sites ( – 94G>A) 
was significantly associated with two 
renal function parameters, eGFR and 
urate excretion. This observation was 
robust to permutation testing and 
remained unchanged aft er assessment 
and correction of population stratifi ca-
tion. Th ese preliminary results were then 
followed by association testing in an 
independent cohort of 677 normotensive 
white subjects from the Kaiser health-
care organization. Again, no association 
was observed for systolic and diastolic 
see original article on page 1070
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Several regulatory sequences may be 
found in the 5  -UTRs, including binding 
sites for proteins aff ecting mRNA stability 
or translation. Th is is the fi rst study to 
demonstrate that the  – 94A allele in the 
5  -UTR of the  DRD1 gene alters its 
expression. However, it remains unclear 
how increased D 1 receptor expression 
 in vitro translates into reduced eGFR 
 in vivo . Th is question becomes even more 
complex when one considers the results 
blood pressure, but the direction-
 consistent eff ect on eGFR was confi rmed: 
the diff erence was most evident among 
13 subjects carrying two copies of the 
minor allele (A) who had signifi cantly 
lower eGFR compared with individuals 
who carry at least one copy of the more 
common G allele. Finally, the authors 
performed  in vitro studies to investigate 
whether the  – 94G>A variant has an eff ect 
on DRD1 expression. Indeed, the density 
of cell-surface-expressed D 1 receptors 
was diff erent in cells transfected with the 
 – 94A sequence as compared with wild 
type. Th e presence of the minor (A) allele 
appeared to significantly increase the 
expression of dopamine D 1  receptors. 
 Th e 5  -UTR, also known as the leader 
sequence, is a particular section of the 
DNA sequence that precedes the coding 
portion of a gene. It is transcribed into 
mRNA but not translated into protein. 
 Table 1  Summary of published studies of DRD1 polymorphisms in association with blood pressure and renal traits 
 Study  Population and design  DRD1 SNP  Phenotype  Findings  Problems and comments 
 Sato  et al. , 2000 16  Japanese; 131 patients 
with essential HTN 
and 136 normotensive 
controls; case – control 
association 
 – 48A>G  Essential hypertension  – 48G allele 
 associated with HTN 
( P =0.01, by crude 
  2 test) 
 Severely underpowered, no 
assessment of population 
stratifi cation, no replication 
 Beige  et al. , 2004 17  White; 493 patients with 
essential HTN and 209 
normotensive controls; 
case – control association 
 – 48A>G  
 – 94G>A 
 Essential hypertension  Not signifi cant for 
either polymor-
phism 
 Limited power, no as-
sessment of population 
stratifi cation 
 Lu  et al. , 2006 18  Georgia Cardiovas-
cular Twin Study; 505 
whites and 407 African 
Americans from a total of 
456 twin pairs; GEE and 
sib-pair TDT 
 – 48A>G  SBP and DBP at rest and 
in response to stress in 
normotensives 
 – 48G allele associ-
ated with lower DBP 
at rest ( P =0.032) and 
in response to stress 
( P =0.046, by GEE); 
TDT not signifi cant 
 Inadequate correction for 
mixed ethnicity, no correc-
tion for multiple testing, no 
replication, TDT approach 
severely underpowered 
 Rao  et al. , 2007 11  Southern California popu-
lation-based twin registry; 
374 whites from 187 twin 
pairs; GEE 
 – 48A>G  
 – 94G>A 
 Albuminuria  Not signifi cant for 
 – 48A>G;  – 94A allele 
protective against 
albuminuria 
( P =0.028, by GEE) 
 Limited power, inadequate 
correction for multiple 
testing, no assessment of 
population stratifi cation, 
no replication 
 Staessen  et al. , 2008 19  FLEMENGHO; 611 whites 
from a family-based 
cohort; quantitative 
association, haplotype 
association, and QTDT 
 – 48A>G  
 – 94G>A  
 – 800C>T 
 SBP, DBP, PRA, aldos-
terone excretion, FeNa, 
FeLi, fractional distal 
reabsorption of Na 
 Not signifi cant 
for SBP, DBP, PRA, 
or  aldosterone 
 excretion by 
single SNP and 
 haplotype tests; 
FeNa lower in  – 94A 
carriers ( P =0.014) 
and fractional distal 
reabsorption of 
Na higher in  – 94A 
 carriers ( P= 0.005) 
 Limited power, inadequate 
correction for multiple 
testing, underpowered 
QTDT approach, no replica-
tion. Signifi cant results 
likely confounded by 
population stratifi cation 
(between-family variance 
was signifi cant by QTDT for 
renal traits) 
 Prasad  et al. , 2008 20  Asian Indians; 196 dia-
betic patients with CKD 
and 225 diabetic controls; 
case – control association 
 – 48A>G  CKD in diabetics  Not signifi cant  Limited power, no assess-
ment of population 
stratifi cation 
 Fung  et al. , 2009 10 
(this issue) 
 Southern California 
 population-based twin 
registry: 428 whites 
from 195 families (GEE); 
 replication in 677 
 normotensive whites 
from the  population-
based Kaiser registry 
(quantitative association) 
 – 48A>G  
 – 94G>A 
 SBP, DBP, creatinine, 
eGFR, serum and urine 
UA, and FeUA 
 Not signifi cant 
for  – 48A>G;  – 94A 
homozygotes with 
lower eGFR and 
FeUA, but not 
 signifi cant for SBP 
or DBP. Association 
with eGFR replicated 
with  P =0.034 
(G  allele protective) 
 Adequately corrected for 
population structure and 
replicated in an inde-
pendent cohort.  In vitro 
studies suggest that the 
risk allele (A) at position 
 – 94 increases D 1 receptor 
expression 
 CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular fi ltration rate; FeLi, fractional excretion of lithium; FeNa, fractional excretion of sodium; 
FeUA, fractional excretion of uric acid; FLEMENGHO, Flemish Study on Environment, Genes and Health Outcomes; GEE, generalized estimating equations; HTN, hypertension; 
PRA, plasma renin activity; QTDT, quantitative transmission disequilibrium testing; SBP, systolic blood pressure; TDT, transmission disequilibrium testing; UA, uric acid. 
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of a prior study, based on the same cohort, 
suggesting a protective eff ect of the  – 94A 
allele against albuminuria. 11 Fung  et al. 10 
hypothesize that altered D 1 receptor 
expression may lead to eff erent arteriole 
vasodilation, which in turn leads to 
diminished capillary pressure and 
reduced GFR ( Figure 1 ). Th e eff ect on 
albuminuria and fractional excretion of 
uric acid may be secondary to diminished 
GFR, although this hypothesis was not 
formally tested. Currently, this mechanism 
remains purely speculative, and further 
functional studies are needed to provide 
validation. 
 Th is work needs to be viewed in the 
context of recent developments in the 
genetic studies of eGFR and chronic kid-
ney disease. Like hypertension, chronic 
kidney disease presents multiple chal-
lenges to geneticists, primarily because of 
complex genetic architecture, a high level 
of heterogeneity, and imperfect pheno-
type definition, all of which severely 
impact the power of genetic studies. 12 As 
a result, large cohorts and careful pheno-
type characterization are needed to 
establish fi rm associations. In addition, 
the advent of high-throughput chip-
based SNP genotyping launched an era 
of large-scale genome-wide association 
(GWA) studies. Th e benefi ts of the mod-
ern GWA design are numerous and 
include lack of bias in selection of candi-
date genes, more robust assessment of 
population stratifi cation or cryptic relat-
edness, imputation-based inference 
about all common SNPs discovered in 
human populations, and the ability to 
perform high-resolution haplotype ana-
lysis as well as surveys of copy-number 
polymorphisms across the genome. Th e 
major drawbacks, however, include the 
high cost of genotyping, and the enor-
mous sample sizes required to overcome 
the issues of multiple testing. Th e fi rst 
GWA study for the eGFR phenotype has 
been published recently. 13 This large 
study involved a genome-wide meta-
analysis of over 2.5 million imputed SNPs 
in 19,877 individuals derived from four 
population-based cohorts, followed by 
replication in an additional 21,466 indi-
viduals. Variants in three genes,  UMOD , 
 SHROOM3 , and  STC , were signifi cantly 
and reproducibly associated with indexes 
of glomerular fi ltration. Notably, mem-
bers of the dopaminergic pathway were 
absent from the list of top signals for 
eGFR. Th erefore, the question arises of 
how one can interpret the results of this 
relatively small candidate gene study in 
the context of a GWA study with an eff ec-
tive sample size that is nearly 20 times 
larger. Inadequate coverage or tagging 
of the dopamine receptor polymor-
phisms by the genome-wide SNP chips 
is unlikely, because both  – 48A>G and 
 – 94G>A SNPs are included in most of 
the SNP panels of commonly used geno-
typing platforms. However, multiple 
other factors can potentially explain this 
lack of reproducibility. For instance, 
association of  DRD1 might be specifi c to 
populations studied by Fung  et al. , 10 and 
not generalizable to other populations. 
Also, differences in the analytical 
approach might have played a role. For 
example, a recessive eff ect of the  – 94A 
allele may be missed in a study analyzed 
under an additive model. Also, diff erent 
covariate adjustment might have masked 
its eff ect. Moreover, multiple limitations 
and inaccuracies of the eGFR phenotype 
might have biased the signal. Similarly to 
the eGFR phenotype, no polymorphisms 
in dopamine receptors were present 
among the top signals of the two largest 
GWA studies of blood pressure and 
hypertension. 14,15 
 In summary, the observations of Fung 
and colleagues 10 are intriguing but 
need to be followed by further func-
tional studies to defi ne the causal mech-
anism. Also, it remains unclear whether 
 – 94A polymorphism contributes sub-
stantially to the risk of chronic kidney 
disease in the general population. As 
more genome-wide genotypes from 
 community-based cohorts become 
publicly available, it will be imperative 
to re-examine genetic variants in the 
dopaminergic system jointly, in a much 
larger data set. Since many genes 
participate in dopamine signaling, a 
pathway-based gene set analysis may be 
helpful in defi ning the role of genetics in 
dopamine-mediated  regulation of renal 
function. 
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 Acute renal failure (ARF) is a sudden 
loss of the kidneys ’ excretory function 
occurring within hours or days after 
an abrupt renal insult. ARF still poses a 
major human, clinical, and socioeconomic 
burden whose incidence and mortality 
have remained considerably high during 
the past 60 years in spite of the improve-
ment of dialysis and acute-care tech-
niques. 1 The etiopathology of ARF is 
usually multifactorial, although incom-
pletely understood. Causes are oft en clas-
sified into (1) prerenal, due to an 
inadequate blood supply (as in hypoten-
sion or arterial obstruction); (2) intrinsic, 
due to functional or structural alterations 
of the renal parenchyma (for example, 
drug-induced nephrotoxicity); and (3) 
postrenal, caused by impairment of urine 
output (for example, ureteral obstruction 
or prostate enlargement). Among them, 
ischemia and nephrotoxicity are the most 
common triggers of ARF in the clinical 
setting. Ischemic ARF is oft en caused by 
hypotension, renal artery thrombosis, or 
surgical clamping of the aorta or the renal 
arteries. In high-risk patients subjected to 
this type of surgery, the incidence of 
ischemic renal dysfunction has been 
reported to be as high as 50 % . 2 An exem-
plifying case of nephrotoxicity is posed by 
cisplatin, a chemotherapeutic drug widely 
used for the treatment of diverse solid 
tumors. Its nephrotoxicity is, however, a 
serious and limiting side effect that 
requires both dosage lowering and patient 
hydration. Despite this, ARF still occurs 
even at low doses and especially upon 
repeated administration. 3 
 In the context of ARF, renal tubular cells 
(RTCs) are damaged, resulting in acute 
tubular necrosis. RTCs are epithelial cells 
highly specialized in the effi  cient trans-
cellular transport of water, electrolytes, 
and macromolecules through highly 
selective, tightly regulated, and adenosine 
triphosphate (ATP)-consuming trans-
porters. ATP availability is thus a critical 
aspect of RTC homeostasis. ATP decline 
occurring during acute renal dam-
age disrupts transport mechanisms, 
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 Potential utility of PPAR  
activation in the prevention of 
ischemic and drug-induced 
acute renal damage 
 Francisco J.  Lopez-Hernandez 1 , 2 and  Jos é M.  Lopez-Novoa 1 
 Acute renal failure induced by renal ischemia or drugs continues to be 
a relevant clinical problem. Li  et al. have demonstrated that proximal 
tubule-restricted peroxisome proliferator–activated receptor-  (PPAR  ) 
expression in transgenic mice reduced cisplatin- and ischemia /
 reperfusion-induced acute renal injury. Their article suggests a role for 
the maintenance of free fatty acid oxidation in the proximal tubule 
as a mechanism of nephroprotection, as well as a potential clinical utility 
of PPAR  activators in the prevention of acute renal failure. 
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